This document is scheduled to be published in the Federal Register on 03/16/2012 and available online at http://federalregister.gov/a/2012-06345, and on FDsys.gov

[Billing Code: 4140-01-P]

DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health

National Cancer Institute Notice of Closed Meeting

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C.

Appendix 2) notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c) (4) and 552b(c) (6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for potential new therapeutics for the treatment of cancer. The outcome of the evaluation will provide information to internal NCI committees that will decide whether NCI should support requests and make available contract resources for development of the potential therapeutic to improve the treatment of various forms of cancer. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Cancer Institute Special Emphasis Panel

NCI Experimental Therapeutics Program (NExT)

Date: April 11, 2012

Time: 8:30AM – 4:30PM

Agenda: To evaluate the NCI Experimental Therapeutics Program Portfolio.

Place: National Institutes of Health Neuroscience Building

6001 Executive Boulevard Room C

Bethesda, MD 20814

Contact Person: Barbara Mroczkowski, PhD

Executive Secretary

NCI Experimental Therapeutics Program

National Cancer Institute, NIH 31 Center Drive, Room 3A44

Bethesda, MD 20817

(301) 496-4291

mroczkowskib@mail.nih.gov

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: March 9, 2012	
Jennifer S. Spaeth Director, Office of Federal Advisory Committee Policy	

[FR Doc. 2012-6345 Filed 03/15/2012 at 8:45 am; Publication Date: 03/16/2012]